Solutions & Services
Therapeutic expertise
Why APICES
APICES is pleased to share that our team has been acknowledged in the PARASEC study, a retrospective prostate cancer study presented at the ASCO GU 2025 Congress and published as a Journal of Clinical Oncology meeting abstract.
In PARASEC, investigators describe subsequent treatment patterns in Spanish prostate cancer patients who received darolutamide in the ARAMIS trial, reflecting standard clinical practice in Spain.
APICES collaborated across multiple activities, including study start-up, project management, monitoring, biostatistics, and medical writing. We would like to thank Bayer and Dr. Javier Puente for the opportunity to contribute and to be included in the acknowledgments, and we congratulate all investigators on the successful completion of this project.
You can find further information in the following link: Treatment patterns in prostate cancer patients who received darolutamide in the ARAMIS trial in Spain: PARASEC study. | Journal of Clinical Oncology
Get the latest clinical insights delivered to your feed or inbox!
On integration, change leadership, and strengthening Apices as one unified organization In a clinical research environment where sponsors value stability, predictability, and quality above all else, organizational change must be approached with care. As APICES...
RWE and HEOR have moved from supporting inputs to decision-critical evidence across development and access. This article summarises what teams are using them for today, how evidence generation is changing, and where AI adds value when paired with the right governance.
Stage III NSCLC care sits at the intersection of multimodal treatment and real-world constraints. The GEOCP-SEOR population-based study describes how patients are managed across Spain, and APICES was acknowledged for supporting the publication through medical editorial assistance.